Literature DB >> 20628556

Medical and Mental Health Status Among Drug Dependent Patients Participating in a Smoking Cessation Treatment Study.

Jennifer E Lima1, Malcolm S Reid, Jennifer L Smith, Yulei Zhang, Huiping Jiang, John Rotrosen, Edward Nunes.   

Abstract

Substance Abusers have a large number of medical and psychiatric problems, and 70-90% are smokers. The aim of this analysis was to examine the prevalence and correlates of medical and psychiatric problems in this sample of drug dependent patients who were participants in a multi-site study of smoking cessation interventions while engaged in substance abuse treatment. Descriptive analyses showed at baseline, 72.8% of participants had at least one medical problem and 64.1% had at least one psychiatric diagnosis. Medical problems correlated strongly with age, smoking severity, and pack-years; Psychiatric problems correlated with gender and ethnicity. Smoking cessation treatment was associated with a moderate reduction in the ASI Medical composite score. More research is needed on the possible effects of combined treatment of substance abuse and concurrent medical and psychiatric problems. Offering smoking cessation in conjunction with primary care may be a way to address the health needs of this population.

Entities:  

Year:  2009        PMID: 20628556      PMCID: PMC2902002          DOI: 10.1177/002204260903900204

Source DB:  PubMed          Journal:  J Drug Issues        ISSN: 0022-0426


  35 in total

1.  The impact of smoking cessation on drug abuse treatment outcome.

Authors:  Stephenie C Lemon; Peter D Friedmann; Michael D Stein
Journal:  Addict Behav       Date:  2003-09       Impact factor: 3.913

2.  Primary medical care and reductions in addiction severity: a prospective cohort study.

Authors:  Richard Saitz; Nicholas J Horton; Mary Jo Larson; Michael Winter; Jeffrey H Samet
Journal:  Addiction       Date:  2005-01       Impact factor: 6.526

3.  Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index.

Authors:  John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch
Journal:  Drug Alcohol Depend       Date:  2006-10-11       Impact factor: 4.492

4.  Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial.

Authors:  E V Nunes; F M Quitkin; S J Donovan; D Deliyannides; K Ocepek-Welikson; T Koenig; R Brady; P J McGrath; G Woody
Journal:  Arch Gen Psychiatry       Date:  1998-02

5.  Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients.

Authors:  Thomas P O'Toole; Eric C Strain; Gary Wand; Mary E McCaul; Matthew Barnhart
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

6.  Effect of primary medical care on addiction and medical severity in substance abuse treatment programs.

Authors:  Peter D Friedmann; Zhiwei Zhang; James Hendrickson; Michael D Stein; Dean R Gerstein
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

7.  Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).

Authors:  Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison
Journal:  J Pain       Date:  2008-01-22       Impact factor: 5.820

Review 8.  The role of depression in the etiology of acute coronary syndrome.

Authors:  Emily D Williams; Andrew Steptoe
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

9.  Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study.

Authors:  B J Rounsaville; T R Kosten; M M Weissman; H D Kleber
Journal:  Arch Gen Psychiatry       Date:  1986-08

10.  Linking alcohol- and drug-dependent adults to primary medical care: a randomized controlled trial of a multi-disciplinary health intervention in a detoxification unit.

Authors:  Jeffrey H Samet; Mary Jo Larson; Nicholas J Horton; Kathleen Doyle; Michael Winter; Richard Saitz
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.